Parabilis医药

最新新闻

• Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Parabilis Medicines, Inc. (PBLS) and Acumen Pharmaceuticals (ABOS)
  TipRanks · 2026/9/17
• BofA Securities Maintains Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/9/17
• Analysts Are Bullish on Top Healthcare Stocks: Parabilis Medicines, Inc. (PBLS), Cormedix (CRMD)
  TipRanks · 2026/8/14
• LifeSci Capital Maintains Parabilis Medicines(PBLS.US) With Buy Rating, Maintains Target Price $42
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  LifeSci Capital Initiates Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $42
  \u5e02\u573a\u8d44\u8baf · 2026/7/18
• BofA Securities Maintains Parabilis Medicines(PBLS.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS)
  TipRanks · 2026/8/15
• 评级变动
  A Quick Look at Today's Ratings for Parabilis Medicines(PBLS.US), With a Forecast Between $40 to $45
  \u5e02\u573a\u8d44\u8baf · 2026/7/7
• 评级变动
  Guggenheim Sticks to Its Buy Rating for Parabilis Medicines, Inc. (PBLS)
  TipRanks · 2026/8/17
• 评级变动
  Parabilis Medicines, Inc. (PBLS) Receives a Buy From LifeSci Capital
  TipRanks · 2026/7/13
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Parabilis Medicines, Inc. (PBLS) and LENZ Therapeutics (LENZ)
  TipRanks · 2026/7/6

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。